The role of the proteasome in ER turnover might explain why CPE was previously only associated with prognosis in ER+/HER2-breast cancer patients, although proteasome activity was also associated with prognosis in ER-breast cancer [19,48,49]. This evidence concerns the gene ERBB2 and breast carcinoma.